Provider Briefing: Aurovela Fe 1.5/30 28 Day Availability in 2026

If your patients have been reporting difficulty filling prescriptions for Aurovela Fe 1.5/30 28 Day, the supply challenges are real and ongoing. This guide provides a clinical and practical overview of the situation for prescribers — including the shortage timeline, prescribing considerations, therapeutically equivalent alternatives, and resources to help your patients maintain contraceptive coverage.

Aurovela Fe 1.5/30 28 Day is a combined oral contraceptive containing Norethindrone Acetate 1.5 mg / Ethinyl Estradiol 30 mcg with 7 days of Ferrous Fumarate (iron) tablets, manufactured by Aurobindo Pharma. It is an AB-rated generic equivalent of Loestrin Fe 1.5/30.

Shortage Timeline

The availability challenges with Aurovela Fe 1.5/30 have developed gradually:

• 2022–2023: Initial reports of Aurobindo Pharma scaling back production of certain Aurovela formulations. Some strengths were reported as discontinued. Pharmacy wholesalers began removing Aurovela SKUs from catalogs.
• 2024: Widespread reports from patients and pharmacists about inability to source Aurovela Fe 1.5/30. Automatic substitutions to Junel Fe 1.5/30 and Microgestin Fe 1.5/30 became routine at major chain pharmacies.
• 2025–2026: Availability remains inconsistent. Some regional wholesalers still carry intermittent supply, but Aurovela Fe 1.5/30 is no longer reliably stocked at most retail pharmacies. The product has not appeared on the FDA's formal drug shortage list for oral contraceptive tablets, but practical availability is limited.

Prescribing Implications

The supply constraints around Aurovela Fe 1.5/30 have several clinical and administrative implications for providers:

Generic Substitution

All AB-rated generics of Norethindrone Acetate 1.5 mg / Ethinyl Estradiol 30 mcg / Ferrous Fumarate are considered therapeutically equivalent by the FDA. In most states, pharmacists can substitute one AB-rated generic for another without prescriber authorization. However:

• Some patients express strong preferences for a specific manufacturer due to perceived differences in tolerability related to inactive ingredients.
• A small number of states require prescriber consent for generic-to-generic substitution when the prescription specifies a brand.
• Insurance formulary preferences may affect which generic is dispensed and at what cost.

Patient Communication

Patients who have been stable on Aurovela Fe 1.5/30 may be anxious about switching manufacturers. It's helpful to proactively address:

• The bioequivalence of AB-rated generics and the FDA standards they must meet
• That minor differences in inactive ingredients rarely cause clinically significant effects
• That switching generics does not require a gap in therapy — patients can transition at any point in their cycle

Prescribing for Availability

Consider writing prescriptions for "Norethindrone Acetate/Ethinyl Estradiol 1.5/30 with Ferrous Fumarate" rather than a specific brand or generic name. This gives the dispensing pharmacy maximum flexibility to fill with whatever equivalent product is in stock.

Current Availability Picture

As of early 2026, the following generics in this formulation category are generally available:

• Junel Fe 1.5/30 (Teva Pharmaceuticals) — widely stocked, most common substitute
• Microgestin Fe 1.5/30 (Mayne Pharma) — good availability at major chains
• Larin Fe 1.5/30 (Novast/Allergan) — available at many retail and mail-order pharmacies
• Blisovi Fe 1.5/30 (Lupin Pharmaceuticals) — available but may have regional variation
• Aurovela Fe 1.5/30 (Aurobindo Pharma) — intermittent, limited availability

For patients who specifically want to locate Aurovela Fe 1.5/30 or any of its equivalents, Medfinder for Providers offers real-time pharmacy stock checking to help identify nearby pharmacies with inventory.

Cost and Access Considerations

Under the ACA contraceptive coverage mandate, most insurance plans cover FDA-approved generic oral contraceptives at $0 copay without prior authorization. Key considerations:

• Formulary alignment: Some plans prefer specific generics. If a patient's pharmacy dispenses a non-preferred generic, the patient may be charged a copay. In these cases, contacting the insurer or switching to the preferred generic resolves the issue.
• Grandfathered plans: Plans grandfathered under the ACA may not cover contraceptives at $0. Patients on these plans may pay $5–$30 per month.
• Cash-pay patients: For uninsured patients, discount programs like GoodRx and SingleCare can reduce the cost of generic Norethindrone Acetate/Ethinyl Estradiol 1.5/30 to approximately $13–$30 per 28-day supply.
• Patient assistance: Planned Parenthood, Title X family planning clinics, and state Medicaid programs provide free or reduced-cost contraception for qualifying patients.

Tools and Resources for Providers

Several tools can help you and your staff manage the Aurovela Fe 1.5/30 availability challenges:

• Medfinder for Providers: Real-time pharmacy availability checking. Direct patients here or use it during clinical encounters to identify nearby pharmacies with stock.
• FDA Drug Shortage Database: Monitor formal shortage listings at accessdata.fda.gov.
• ASHP Drug Shortages Resource Center: The American Society of Health-System Pharmacists maintains up-to-date shortage information and clinical alternatives.
• Telehealth referral: For patients who need rapid prescription changes, telehealth platforms specializing in contraception (Nurx, SimpleHealth, Planned Parenthood Direct) can assist with timely prescription adjustments.

Looking Ahead

The generic oral contraceptive market is competitive, and while specific products like Aurovela Fe 1.5/30 may face ongoing supply issues, the overall availability of Norethindrone Acetate/Ethinyl Estradiol combination products remains stable. Multiple manufacturers continue to produce AB-rated equivalents, ensuring patients have access to this formulation even when one brand is unavailable.

Providers can help by:

• Writing flexible prescriptions that allow generic substitution
• Proactively discussing alternative generics with patients
• Directing patients to Medfinder for real-time stock information
• Maintaining awareness of supply chain updates through FDA and ASHP resources

Final Thoughts

The Aurovela Fe 1.5/30 shortage is a practical challenge, but the clinical impact can be minimized with proactive prescribing and patient education. Multiple therapeutically equivalent alternatives exist, insurance coverage under the ACA remains strong, and tools like Medfinder are making it easier for both providers and patients to navigate availability issues in real time.

For patient-facing resources to share with your patients, see our articles on what patients need to know about the shortage, alternatives to Aurovela Fe 1.5/30, and how patients can save money on their prescription.